A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
Sarah C. Rutherford(NewYork–Presbyterian Hospital), Peter Martin(Northwestern University), Kseniya Gololobova(Cornell University), Riyaad Rahim(NewYork–Presbyterian Hospital), John N. Allan(Cornell University), John P. Leonard(New York University), Silvia Senese(University of California, Los Angeles), Jennifer Santamala(Cornell University), Koen van Besien(University Hospitals of Cleveland), Adrienne A. Phillips(Palmetto Hematology Oncology), Jia Ruan(Cornell University), Kristy L. Richards(University of North Carolina at Chapel Hill), Leandro Cerchietti(Cornell University), Usama Gergis(Thomas Jefferson University Hospital), Trisha Ali-Shaw(Cornell University), Tsiporah B. Shore(Cornell University), Jingmei Hsu(Cancer Research Institute), Zhengming Chen(Cornell University), Sebastian Mayer(Mount Sinai Hospital), Richard R. Furman(Cornell University), Arcania Garcia(Cornell University), Rossella Marullo(Regeneron (United States))
Cited by 8
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k